Elevate Medical Affairs Podcast Channel

Recorded at the MAPS 2024 Annual Meeting in Puerto Rico following a workshop on modular content in which all of today’s speakers were faculty. Lead by the Digital FAWG’s Jennifer Riggins and Steve Casey, today’s panelists touch on the topic of modular content in the following areas: Inspiration and ImpactContent Compliance & ApprovalMSL UtilizationTraining & EvolutionThe Technology StackThe Future of Modular Content For more information on Modular Content, explore the MAPS White Paper: “Modular Content in Medical Affairs: The Foundation of Omnichannel Engagement” HERE: https://medicalaffairs.org/modular-content-omnichannel-engagement/

As the sources of data and technologies needed to make sense of data expand, opportunities exist for further integrating Real-World Evidence (RWE) and Health Economics and Outcomes Research (HEOR) alongside traditional approaches when planning data generation activities to support new product registration, access, and use. Here we speak with experts from Lumanity about the Integrated Evidence Generation Planning (IEGP) process and how to overcome the barriers to success. 

Here we speak with Kate Davies, Nurse Educator at London South Bank University and expert in clinical endocrine research focusing on genetics in short stature, clinical trials, and differences in sex development. Throughout Kate's research and work as a pediatric nurse, she has developed expertise in engaging with patient communities, often providing trusted information to these groups and also learning about the real-world experiences of patients in the context of treatment and clinical trials. Here is what a patient advocate wants Medical Affairs to know about patient engagement -- and join us at our LinkedIn discussion on this topic to ask your own questions about engaging with patients. 

Getting the most impact from a publication requires being able to define who the audience is and how to reach them, across both journals and online channels, especially in complex/niche cases. In this podcast, we’ll discuss the benefits of taking an analytical approach.

When you think about innovation in Medical Affairs, perhaps the first things that come to mind are GenAI or maybe new approaches to KOL network mapping. But what about innovation in the ways we approach the profession itself? What about innovation in how we continue to evolve our own skills and understanding of our roles in industry and beyond? Here we speak with Tim Mikelhashvili, CEO of Amedea Pharma about innovation in Medical Affairs leadership -- and innovation for leaders. We also look forward to Tim's 2024 Medical Affairs Innovation Olympics. Enter your innovative idea now or register to attend!

A PubMed search on the day this was written finds 36,735 new publications in the last 24 hours. Adding the word “oncology” narrows the number to 4,334. Substituting “lung cancer” for “oncology” results in 534 articles. How many of these do you think your HCPs and KOLs will be able to read before the next batch of publications comes out tomorrow? This is to say that publishing a scientific study or article can feel like squeezing an eyedropper into the ocean and it is the job of the publication’s team to ensure this drop-in-the-ocean has impact — especially when publishing a study with the potential to change clinical practice. Here we learn practical tips straight from the source – namely, experts at Wiley. How can you translate peer-reviewed publications to clinical impact? How can licensing extend (or perhaps restrict…) the reach of published research? How can publications be leveraged as the hub of an omnichannel approach? Listen to learn more.

Is there a correlation between a higher journal impact factor and increased reach and engagement? The answer has always been, "Of course!" But now with companies driving their own engagement, and alternatives to the journals becoming more mainstream and accepted everyday, the answer is more nuanced. Join our expert guests from Digital Science to discuss the NEW metrics of journal publication.

Carolina Lau, Associate VP at United Therapeutics, and Sonia Rivera, VP at Veeva Link, dive into the art of optimizing medical congresses. They share strategies for selecting the right events and enhancing collaboration across teams. The conversation covers the vital role of technology and data in maximizing engagement with Key Opinion Leaders. They emphasize the importance of strategic planning post-COVID and innovative approaches that leverage real-time insights for impactful conference outcomes.

Diana Morgenstern, a Fellow of the American College of Physicians and an Executive Strategist at IQVIA, alongside Javier Lopez-Molina, Senior Director at IQVIA, delve into the critical need for measuring the impact of Medical Affairs. They discuss the transition from a support role to strategic leadership, exploring the challenges of demonstrating measurable outcomes. Highlighting advancements in machine learning for attribution, they emphasize a holistic approach to data-driven evaluations and advocate for embracing change in mindset and tools within the industry.

As Medical Affairs professionals, many of us have moved from first careers in academia or healthcare. What did your colleagues say when you told them you were transitioning to pharma? Did they say you were going to the "dark side"? In this episode, we speak with Robert Atkinson, President of the Information Technology and Innovation Foundation and author of the recently published book, Technology Fears and Scapegoats: 40 Myths About Privacy, Jobs, AI, and Today’s Innovation Economy. And we explore the origins of negative opinions of the pharmaceutical industry, and whether a for-profit model can support both innovation and the society's best interests.